pulmonary arterial hypertension

Showing 9 posts of 9 posts found.

Tiakis Biotech appoints Christoph Schmidt to supervisory board

May 22, 2025
Research and Development Cardiology, Tiakis Biotech, cardiovascular diseases, pulmonary arterial hypertension

Tiakis Biotech has announced the appointment of Christoph Schmidt to its supervisory board. Based in Kiel, Germany, the clinical-stage biotech …

FDA approves Merck’s Winrevair for PAH treatment

March 27, 2024
Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024
Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …

credit_rich_s

United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure

April 9, 2019
Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension

United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …

EMA inside

Actelion’s Uptravi and rare bleeding disorder drug get positive EMA decisions

February 1, 2016
Sales and Marketing CHMP, EMA, Uptravi, pulmonary arterial hypertension, selexipag

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has issued positive opinions on …

Actelion logo

Actelion’s Uptravi goes on sale

January 5, 2016
Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag

Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …

Actelion building

Actelion ready to launch Uptravi after FDA approval

December 22, 2015
Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag

Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …

Pfizer

Pfizer’s Revatio extends Europe PAH licence

May 9, 2011
Sales and Marketing PAH, Pfizer, pulmonary arterial hypertension, revatio

Pfizer’s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children.The European Commission has …

Pfizer's New York headquarters

Pfizer withdraws hypertension drug Thelin

December 14, 2010
Sales and Marketing PAH, Pfizer, Thelin, liver damage, liver toxicity, patient safety, pulmonary arterial hypertension, sitaxentan

Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …

The Gateway to Local Adoption Series

Latest content